PRIMARY STUDY
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis
Key Findings: Although there was no remission, the physician's overall assessment of illness severity and patients' subjective reports suggest improved quality-of-life outcomes in patients taking CBD-rich botanical extract.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 60
Study Result: Positive
Research Location(s): United Kingdom
Year of Pub: 2019
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabinoid (unspecified)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Sub-Ratio: 0:1 (THC:CBD)
Dosage: CBD (50 to 250 mg in CBD rich botanical extract with a small percentage of THC)
Route of Administration: Oral (Ingestion)
Citation: Irving PM, et al. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. Inflamm Bowel Dis. 2018; 24:714-724. doi: 10.1093/ibd/izy002
Authors: Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C, Lindsay JO, Taylor A, Barron R, Wright S
